Tosk
Sunnyvale, US · Delaware corporation
Tosk is a pharmaceutical company developing therapeutics for oncology, including approaches to reduce treatment-limiting side effects of cancer therapy, drawing on Drosophila-based drug discovery models. Its leadership and advisory board consist of pharmaceutical industry executives, cancer researchers, and clinical oncologists.
Founders & leadership
BF
Brian FrenzelinPresident, CEO, and Director
OS
Om SrivastavaExecutive Vice President, Chief of Technical Operations and Product Development
SY
Stephen YanofskyinVice President Research
CG
CHARLES GARVINNamed on SEC filing
Board
HC
HAROLD CROWChairman
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 3 rounds · 2011–2022
▶$100KraisedSep 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedSep 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian FrenzelExecutive Officer
- Offering amount
- $3M
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedOct 2019 · 56 investors · PharmaceuticalsRule 506(b)
▶$3.1MraisedOct 2019 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- HAROLD CROWDirector
- BRIAN FRENZELExecutive Officer, Director
- CHARLES GARVINDirector
- Offering amount
- $5.1M
- Amount sold
- $3.1M
- Minimum investment
- $12K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedAug 2014 · 74 investors · PharmaceuticalsRule 506(b)
▶$5.4MraisedAug 2014 · 74 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- BRIAN FRENZELExecutive Officer, Director
- HAROLD CROWDirector
- CHARLES GARVINDirector
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- Minimum investment
- $8.1K
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapStoke Therapeutics15 shared keywords
Kite Pharma6 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Seeking Alpha6 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Rocket Pharma6 shared keywordsRocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders. The company creates potentially curative treatments at the genetic level for inherited and rare diseases.
Companies competing with Tosk for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $95.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $93.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Tosk do?
- Tosk is a pharmaceutical company developing therapeutics for oncology, including approaches to reduce treatment-limiting side effects of cancer therapy, drawing on Drosophila-based drug discovery models. Its leadership and advisory board consist of pharmaceutical industry executives, cancer researchers, and clinical oncologists.
- How much funding has Tosk raised?
- Tosk has disclosed $8.6M raised across 3 rounds.
- Where is Tosk headquartered?
- Tosk is headquartered in Sunnyvale, US.